These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 7966058)
21. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Ribeiro AC; Laurindo IM; Guedes LK; Saad CG; Moraes JC; Silva CA; Bonfa E Arthritis Care Res (Hoboken); 2013 Mar; 65(3):476-80. PubMed ID: 22949223 [TBL] [Abstract][Full Text] [Related]
22. [Safety and immunogenicity of split vaccines of influenza viruses]. Zhu CL; Fang HH; Zhu FC; Wang YQ; Wu XL; Xue FB; Shen YJ; Lian JZ Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):207-9. PubMed ID: 15640848 [TBL] [Abstract][Full Text] [Related]
23. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949 [TBL] [Abstract][Full Text] [Related]
24. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Park CL; Frank AL; Sullivan M; Jindal P; Baxter BD Pediatrics; 1996 Aug; 98(2 Pt 1):196-200. PubMed ID: 8692617 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456 [TBL] [Abstract][Full Text] [Related]
26. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Kapetanovic MC; Saxne T; Nilsson JA; Geborek P Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801 [TBL] [Abstract][Full Text] [Related]
27. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly]. Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034 [TBL] [Abstract][Full Text] [Related]
28. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Mamula P; Markowitz JE; Piccoli DA; Klimov A; Cohen L; Baldassano RN Clin Gastroenterol Hepatol; 2007 Jul; 5(7):851-6. PubMed ID: 17544875 [TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age. Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305 [TBL] [Abstract][Full Text] [Related]
31. Implementation of universal influenza immunization recommendations for healthy young children: results of a randomized, controlled trial with registry-based recall. Kempe A; Daley MF; Barrow J; Allred N; Hester N; Beaty BL; Crane LA; Pearson K; Berman S Pediatrics; 2005 Jan; 115(1):146-54. PubMed ID: 15629993 [TBL] [Abstract][Full Text] [Related]
32. A comparative immunogenicity-reactogenicity dose-response study of influenza vaccine. Guarnaccia S; Peters SM; Habib F; Mancuso GR; Dibenedetto SP; Espey M; Bellanti JA Ann Allergy; 1990 Sep; 65(3):218-21. PubMed ID: 2403227 [TBL] [Abstract][Full Text] [Related]
33. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. de Bruijn IA; Nauta J; Gerez L; Palache AM Virus Res; 2004 Jul; 103(1-2):139-45. PubMed ID: 15163502 [TBL] [Abstract][Full Text] [Related]
34. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial. Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953 [TBL] [Abstract][Full Text] [Related]
35. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330 [TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131 [TBL] [Abstract][Full Text] [Related]
37. Specific antibody response after influenza immunization in systemic lupus erythematosus. Abu-Shakra M; Press J; Varsano N; Levy V; Mendelson E; Sukenik S; Buskila D J Rheumatol; 2002 Dec; 29(12):2555-7. PubMed ID: 12465151 [TBL] [Abstract][Full Text] [Related]
38. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Ruf BR; Colberg K; Frick M; Preusche A Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073 [TBL] [Abstract][Full Text] [Related]